Camp4 Therapeutics annual diluted eps
Diluted EPSBasic EPS
2022
2023
2024
2025
Camp4 Therapeutics EPS History: Annual & Quarterly (CAMP)
Camp4 Therapeutics's diluted EPS was -$2.65 for fiscal 2025.
View full Camp4 Therapeutics company overviewCamp4 Therapeutics annual diluted eps history
| Fiscal year | Period ended | Diluted EPS | Basic EPS | Change | Growth |
|---|---|---|---|---|---|
| 2025 | 2025-12-31 | -$2.65 | -$2.65 | $8.39 | — |
| 2024 | 2024-12-31 | -$11.04 | -$11.04 | $113.76 | — |
| 2023 | 2023-12-31 | -$124.80 | -$124.80 | -$121.16 | — |
| 2022 | 2022-12-31 | -$3.64 | -$3.64 | — | — |
Camp4 Therapeutics quarterly diluted eps
Diluted EPSBasic EPS
Q3.23
Q1.24
Q2.24
Q3.24
Q1.25
Q2.25
Q3.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Diluted EPS | Basic EPS | Change | YoY change |
|---|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | -$0.58 | -$0.58 | $0.04 | — |
| Q1 2026 | 2026-03-31 | -$0.32 | -$0.32 | $0.30 | — |
| Q3 2025 | 2025-09-30 | -$0.55 | -$0.55 | $23.64 | — |
| Q2 2025 | 2025-06-30 | -$0.62 | -$0.62 | $25.38 | — |
| Q1 2025 | 2025-03-31 | -$0.62 | -$0.62 | $25.95 | — |
| Q3 2024 | 2024-09-30 | -$24.19 | -$24.19 | $5.02 | — |
| Q2 2024 | 2024-06-30 | -$26.00 | -$26.00 | — | — |
| Q1 2024 | 2024-03-31 | -$26.57 | -$26.57 | — | — |
| Q3 2023 | 2023-09-30 | -$29.21 | -$29.21 | — | — |
Camp4 Therapeutics diluted eps trends
Between the periods ended 2022-12-31 and 2025-12-31, Camp4 Therapeutics's diluted eps increased from -$3.64 to -$2.65, a change of $0.99. The latest reported quarter, Q2 2026, shows -$0.58.
About the metric
What earnings per share (EPS) means
Earnings per share (EPS) shows how much profit or loss is attributable to each common share. Diluted EPS includes the potential effect of convertible securities, options, and other instruments that could increase the share count, while basic EPS uses the weighted-average common shares actually outstanding.
Calculation and source
SEC-reported diluted and basic EPS
TickerStat displays diluted and basic earnings per share from SEC filings. Historical EPS values are adjusted to the current share basis when SEC-reported stock-split conversion ratios are available; they are not analyst estimates or earnings forecasts. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Camp4 Therapeutics source filings ↗Community posts
CAMP4 receives UK authorization for its first SYNGAP1 clinical study
CAMP4 Therapeutics ($CAMP) received UK authorization to include sites in its global Phase 1/2 study of CMP002, an investigational treatment for SYNGAP1-related disorder. The decision follows earlier clearances in Australia and Argentina, wh ...